


AMENDMENTS

Please replace the claims, including all prior versions, with the listing of claims below.

LISTING OF CLAIMS:

1. (Currently amended) A methyldiene oxazolidinone compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof:



(1)

wherein X represents an oxygen or sulfur atom;

R¹ represents hydrogen, cyano or methyl group; and

R² independently represents hydrogen atom, cyano group, alkyl group, halogen atom, acetoxy group, ethoxycarbonyl group, hydroxy group, hydroxyimino group, methoxyimino group or aminoethyl group, or a unsaturated 5-membered heterocyclic substituent containing one or more hetero atoms selected from the group consisting of oxygen, nitrogen and sulfur; cyano, ethoxycarbonyl, methyl, formyl, carboxy, CN(NO₂), CH(NOCH₃), C(NON)CH₃, C(NOCH₃)CH₃, CH(OH)CH₃, CH(OAc)CH₃, CH(OCOCH₂Cl)CH₃, CH(OCOCHCl₂)CH₃, 3-(3-thiophenyl isoxazolyl)- or 3-(3-isothiazolyl)-isoxazolyl-; and

n represents an integer 1 or 2.

2. (Canceled)

3. (Original) The compound according to claim 1, which is N-[[[(5S)-3-[3-fluoro-4-(3-dicyanomethyldienepyrrrolidin-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, N-[[[(5S)-


3-[3-fluoro-4-((3-(1-ethoxycarbonyl-1-cyano)methylidene)pyrrolidin-1-yl)-phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-(3-cyano-methylidenepyrrolidin-1-yl)-phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide,

N-[[[(5S)-3-[3-fluoro-4-((3-(1-methyl-1-cyano)methylidene)pyrrolidin-1-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-(1-cyano-2-ethoxycarbonylethylidene)piperidin-1-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[(5S)-3-[3-fluoro-4-(4-dicyanomethylidenepyrrolidin-1-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-((4-(1-ethoxycarbonyl-1-cyano)-methylidene)piperidinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-cyanomethylidenepiperidinyl)-phenyl]-2-oxo-5-oxazolidinyl)methyl]-acetamide, N-[[[(5S)-3-[3-fluoro-4-((4-(3-thiophen-2-yl-5-isoxazolyl)methylidene)-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-((4-(3-(3-methyl-isothiazol-4-yl)-isoxazolyl)methylidene)piperidinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-((4-ethoxycarbonyl-methylidene)piperidinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-methylcarbonylmethylidenepiperidinyl)phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-(1-ethoxycarbonylethylidene)-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-carboxymethylidenepiperidinyl)-phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-((4-(1-ethoxycarbonyl-1-chloro)methylidene)piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-(1-cyanoethylidene)piperidinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-(2-oxoethylidene)piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-(2-hydroxyiminoethylidene)piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-(2-methoxyiminoethylidene)piperidinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-(2-hydroxyiminopropylidene)piperidinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-(2-methoxyimino-propylidene)piperidinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-(2-hydroxypropylidene)piperidinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-acetamide, N-[[[(5S)-


3-[3-fluoro-4-(4-(2-acetoxypiperidinyl)-phenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-(2-(chloroacetoxy)propylidene)piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-(2-(dichloroacetoxy)propylidene)piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-(cyano-methylidene)piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide, or a hydro-chloride salt thereof.

4. (Original) The compound according to claim 1, wherein the pharmaceutically acceptable salt is a methanesulfonate, fumarate, hydrobromide salt, citrate, maleate, phosphate, sulfate, hydrochloride salt or a sodium salt.


5. (Currently amended) A method for preparing a compound of formula (1) which comprises reacting a compound of formula (2) with a compound of formula (3) in the presence of a catalyst, using or without using a solvent:



(1)



(2)



(3)

wherein X represents an oxygen or sulfur atom;

R^1 represents hydrogen, cyano or methyl group; and

R^2 ~~independently represents hydrogen atom, cyano group, alkyl group, halogen atom, acetoxyl group, ethoxycarbonyl group, hydroxy group, hydroxyimino group, methoxyimino group or aminoethyl group, or a unsaturated 5-membered heterocyclic substituent containing one or more hetero atoms selected from the group consisting of oxygen, nitrogen and sulfur~~ cyano, ethoxycarbonyl, methyl, formyl, carboxy, CN(NOH), CH(NOCH₃), C(NON)CH₃, C(NOCH₃)CH₃, CH(OH)CH₃, CH(OAc)CH₃, CH(OCOCH₂Cl)CH₃, CH(OCOCHCl₂)CH₃, 3-(3-thiophenyl isoxazolyl)- or 3-(3-isothiazolyl)-isoxazolyl-; and

n represents an integer 1 or 2, wherein the catalyst is selected from the group consisting of alumina, ammonia, triethylamine, pyridine, piperidine, potassium fluoride, cerium fluoride and titanium chloride.




6. (Canceled)

7. (Original) The method according to claim 5, wherein the solvent is dichloromethane or benzene.

8. (Canceled)

9. (Original) The method according to claim 5, wherein the reaction is carried out at room temperature or at 50 – 100°C.

10. (Currently amended) A method for preparing a compound of formula (1) which comprises reacting a compound of formula (2) with a compound of formula (4) using a base and a solvent:



wherein X represents an oxygen or sulfur atom;

R¹ represents hydrogen, cyano or methyl group; and

R² independently represents hydrogen atom, cyano group, alkyl group, halogen atom, acetoxymethyl group, ethoxycarbonyl group, hydroxy group, hydroxyimino group, methoxyimino group or aminoethyl group, or a unsaturated 5-membered heterocyclic substituent containing one or more hetero atoms selected from the group consisting of oxygen, nitrogen and sulfur; cyano, ethoxycarbonyl, methyl, formyl, carboxy, CN(NOH), CH(NOCH₃), C(NON)CH₃, C(NOCH₃)CH₃, CH(OH)CH₃, CH(OAc)CH₃, CH(OCOCH₂Cl)CH₃, CH(OCOCHCl₂)CH₃, 3-(3-thiophenyl isoxazolyl)- or 3-(3-isothiazolyl)-isoxazolyl-; and

n represents an integer 1 or 2, wherein the solvent is selected from the group consisting of tetrahydrofuran, dimethylethane and dimethylformamide and wherein the base is sodium hydride or potassium t-butoxide.

11. (Canceled)

12. (Canceled)

13. (Original) The method according to claim 10, wherein the reaction is carried out at room temperature or at 40 – 100°C.